Arun Upadhyay
About
Arun Upadhyay is from Malvern, PA. Arun works in the following industries: "Biotechnology Research". Arun is currently Senior Vice President and Head of R&D at Ocugen, located in Malvern, Pennsylvania, United States. In Arun's previous role as a VP and Head of R&D at Ocugen, Arun worked in until Jan 2022. Prior to joining Ocugen, Arun was a Senior Director, Head of Discovery at Ocugen and held the position of Senior Director, Head of Discovery at Malvern, Pennsylvania, United States. Prior to that, Arun was a Senior/Principal Scientist at Ocugen, based in Malvern, Pennsylvania from Feb 2017 to Nov 2018. Arun started working as Research Scientist and Program Lead at University of Colorado in Greater Denver Area in Oct 2014. From Dec 2010 to Oct 2014, Arun was Postdoctoral Fellow at University of Colorado Denver, based in Denver, Colorado. Prior to that, Arun was a Research Associate at NII - National Institute of Immunology, based in New Delhi Area, India from Jul 2010 to Nov 2010. Arun started working as PhD at NII - National Institute of Immunology in New Delhi Area, India in Jul 2005.
You can find Arun Upadhyay's email on finalScout.com. FinalScout is a popular professional database with more than 500 million business professionals and over 200 million company profiles.
Arun Upadhyay's current jobs
Ocugen, Inc. is a biopharmaceutical company developing novel solutions to medical challenges. Focused on infectious diseases , such as vaccine for SARS-CoV-2 and discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Leading COVID-19 vaccine development and groundbreaking modifier gene therapy platform based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410) for the treatment of genetically diverse inherited retinal disorders. Developing novel biologic therapy (OCU200) for wet-AMD, DME and diabetic retinopathy.
Arun Upadhyay's past jobs
Molecular design, and synthesis of novel therapeutics for the treatment ocular diseases. Process, analytical and formulation development of therapeutic proteins (mAbs, Growth Factors, and Fusion Proteins). Biophysical characterization and stability evaluation of mAbs, growth factors, and viral vectors. Drug-delivery systems based on bio polymers, viral vectors, lipids based nanosystem for targeted delivery of DNA, RNA, protein and small molecules to ocular, brain and lung delivery. Preclinical efficacy in animal models.
Memory antibodies response from polymer particles based vaccine delivery system. Development of adjuvant vaccine formulation.
• Process development, manufacturing, biochemical characterisation, stability evaluation of various biologicals • Understanding protein aggregation process during recombinant protein production in E. coli
Characterization of immunogenic proteins from clinical isolates of Mycobacterium tuberculosis and assessment of immune responses